These results indicated that combination targeting of PARP1 and ACSL1 may be a potential therapeutic strategy to improve the overall survival in BRCA through suppressing the MAPK, mTOR and NF-kB signal pathways to induce apoptosis, autophagy and prevent the inflammatory processes involved in cancer metastasis. This evidence concerns the gene PARP1 and cancer.